Modern Views about the Association of Non-Alcoholic Fatty Liver Disease and Cardiovascular Pathology
https://doi.org/10.31550/1727-2378-2024-23-4-27-31
Abstract
Aim. Based on current literature data, to evaluate the association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD), to consider the pathophysiological mechanisms underlying this relationship, and to indicate methods for reducing cardiometabolic risk in patients with NAFLD.
Key points. NAFLD occupies a leading position in the structure of chronic liver diseases, is one of the manifestations of metabolic syndrome and is closely associated with CVD. The relationship between the prevalence of NAFLD and CVD has been established in numerous studies. CVD is significantly more severe in patients with NAFLD. A number of meta-analyses have documented a direct association between NAFLD and cardiovascular mortality. Many pathophysiological mechanisms of development of these two diseases coincide. Some molecular changes that play an important role in NAFLD are also involved in the formation of CVD. Patients with NAFLD often have atherosclerosis, which also underlies the formation of CVD.
Conclusion. All modern international and Russian recommendations for the management of patients with NAFLD pay significant attention to the advisability of CVD screening and the need to reduce cardiometabolic risk in patients with NAFLD through lifestyle modification (optimizing diet, weight loss, increasing physical activity), using statin medications, ursodeoxycholic acid and ademetionine.
About the Authors
Yu. L. Tonkikh
Federal Research Centre “Krasnoyarsk Science Centre” of the Siberian Branch of Russian Academy of Science, separate division “Scientific Research Institute of medical problems of the North”
Russian Federation
Russian Federation
Tonkikh, Yu.L.
3-g Partizan Zheleznyak Str., Krasnoyarsk, 660022
A. V. Vasyutin
Federal Research Centre “Krasnoyarsk Science Centre” of the Siberian Branch of Russian Academy of Science, separate division “Scientific Research Institute of medical problems of the North”
Russian Federation
Russian Federation
Vasyutin, A.V.
3-g Partizan Zheleznyak Str., Krasnoyarsk, 660022
V. V. Tsukanov
Federal Research Centre “Krasnoyarsk Science Centre” of the Siberian Branch of Russian Academy of Science, separate division “Scientific Research Institute of medical problems of the North”
Russian Federation
Russian Federation
Tsukanov, V.V.
3-g Partizan Zheleznyak Str., Krasnoyarsk, 660022
References
1. Younossi Z., Tacke F., Arrese M., Chander Sharma B. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–82. DOI: 10.1002/hep.30251
2. Younossi Z.M., Golabi P., Paik J.M., Henry A. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47. DOI: 10.1097/HEP.0000000000000004
3. Ivashkin V.T., Drapkina O.M., Mayev I.V., Trukhmanov A.S. et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):31–41. (in Russian)
4. Quek J., Chan K.E., Wong Z.Y., Tan C. et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2023;8(1):20–30. DOI: 10.1016/S2468-1253(22)00317-X
5. Ajmera V., Cepin S., Tesfai K., Hofflich H. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol. 2023;78(3):471–8. DOI: 10.1016/j.jhep.2022.11.010
6. Lonardo A., Ballestri S., Marchesini G., Angulo P., Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig. Liver Dis. 2015;47(3):181–90. DOI: 10.1016/j.dld.2014.09.020
7. Chen B., Tang W.H.W., Rodriguez M., Corey K.E. et al. NAFLD in cardiovascular diseases: a contributor or comorbidity? Semin. Liver Dis. 2022;42(4):465–74. DOI: 10.1055/s-0042-1757712
8. Chalasani N., Younossi Z., Lavine J.E., Charlton M. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. DOI: 10.1002/hep.29367
9. Pipitone R.M., Ciccioli C., Infantino G., La Mantia C. et al. MAFLD: a multisystem disease. Ther. Adv. Endocrinol. Metab. 2023;14:20420188221145549. DOI: 10.1177/20420188221145549
10. Simon T.G., Roelstraete B., Hagström H., Sundström J. et al. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71(9):1867–75. DOI: 10.1136/gutjnl-2021-325724
11. Xiao J., Ng C.H., Chan K.E., Fu C. et al. Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD — an umbrella overview of systematic review of meta-analysis. J. Clin. Exp. Hepatol. 2023;13(4):656–65. DOI: 10.1016/j.jceh.2022.11.006
12. Minhas A.M.K., Jain V., Maqsood M.H., Pandey A. et al. Nonalcoholic fatty liver disease, heart failure, and long-term mortality: insights from the national health and nutrition examination survey. Curr. Probl. Cardiol. 2022;47(12):101333. DOI: 10.1016/j.cpcardiol.2022.101333
13. Fu C.E., Ng C.H., Yong J.N., Chan K.E. et al. A meta-analysis on associated risk of mortality in nonalcoholic fatty liver disease. Endocr. Pract. 2023;29(1):33–9. DOI: 10.1016/j.eprac.2022.10.007
14. Targher G., Byrne C.D., Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9): 1691–705. DOI: 10.1136/gutjnl-2020-320622
15. Toh J.Z.K., Pan X.H., Tay P.W.L., Ng C.H. et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2022;20(11):2462–73.e10. DOI: 10.1016/j.cgh.2021.09.021
16. Ismaiel A., Popa S.L., Dumitrascu D.L. Acute coronary syndromes and nonalcoholic fatty liver disease: “un affaire de coeur”. Can. J. Gastroenterol. Hepatol. 2020;2020:8825615. DOI: 10.1155/2020/8825615
17. Polyzos S.A., Kechagias S., Tsochatzis E.A. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment. Pharmacol. Ther. 2021;54(8):1013–25. DOI: 10.1111/apt.16575
18. Abosheaishaa H., Hussein M., Ghallab M., Abdelhamid M. et al. Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: a systematic review and meta-analysis. Diabetes Metab. Syndr. 2024;18(1):102938. DOI: 10.1016/j.dsx.2023.102938
19. Mahfood Haddad T., Hamdeh S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab. Syndr. 2017;11(suppl.1):S209–16. DOI: 10.1016/j.dsx.2016.12.033
20. Targher G., Byrne C.D., Lonardo A., Zoppini G. et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J. Hepatol. 2016;65(3):589–600. DOI: 10.1016/j.jhep.2016.05.013
21. Wu S., Wu F., Ding Y., Hou J. et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci. Rep. 2016;6:33386. DOI: 10.1038/srep33386
22. Bisaccia G., Ricci F., Khanji M.Y., Sorella A. et al. Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis. Curr. Probl. Cardiol. 2023;48(6):101643. DOI: 10.1016/j.cpcardiol.2023.101643
23. Marchesini G., Day C.P., Dufour J.F., Canbay A. et al. EASL-EASDEASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004
24. Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. DOI: 10.1097/HEP.0000000000000323
25. Chitturi S., Wong V.W., Chan W.K., Wong G.L. et al. The Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017 — part 2: management and special groups. J. Gastroenterol. Hepatol. 2018;33(1):86–98. DOI: 10.1111/jgh.13856
26. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Kotovskaya Yu.V. et al. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for preventive cardiology on diagnosis and treatment of non-alcoholic liver disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104–40. (in Russian). DOI: 10.22416/1382-43762022-32-4-104-140
27. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 2023;79(6):1542–56. DOI: 10.1016/j.jhep.2023.06.003
28. Tsukanov V.V., Osipenko M.F., Beloborodova E.V., Livzan M.A. et al. Practical aspects of clinical manifestations, pathogenesis and therapy of alcoholic liver disease and nonalcoholic fatty liver disease: expert opinion. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(4):7–13. (in Russian). DOI: 10.22416/1382-4376-2023-33-4-7-13
29. Tsukanov V.V., Vasyutin A.V., Tonkikh Yu.L. New aspects of non-alcoholic fatty liver disease. Doctor.Ru. 2021;20(4):33–9. (in Russian). DOI: 10.31550/1727-2378-2021-20-4-33-39
30. Worm N. Beyond body weight-loss: dietary strategies targeting intrahepatic fat in NAFLD. Nutrients. 2020;12(5):1316. DOI: 10.3390/nu12051316
31. Chaaba R., Bouaziz A., Ben Amor A., Mnif W. et al. Fatty acid profile and genetic variants of proteins involved in fatty acid metabolism could be considered as disease predictor. Diagnostics (Basel). 2023;13(5):979. DOI: 10.3390/diagnostics13050979
32. Mehta A., Lee T.B., Alebna P., Grandhi G.R. et al. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia. J. Clin. Lipidol. 2023;17(6):828–33. DOI: 10.1016/j.jacl.2023.09.003
33. Schinzari F., Cardillo C. Intricacies of the endothelin system in human obesity: role in the development of complications and potential as a therapeutic target. Can. J. Physiol. Pharmacol. 2020;98(9):563–9. DOI: 10.1139/cjpp-2019-0651
34. Ismaiel A., Dumitraşcu D.L. Cardiovascular risk in fatty liver disease: the liver-heart axis-literature review. Front. Med. (Lausanne). 2019;6:202. DOI: 10.3389/fmed.2019.00202
35. Abdallah L.R., de Matos R.C., E Souza Y.P.D.M., Vieira-Soares D. et al. Non-alcoholic fatty liver disease and its links with inflammation and atherosclerosis. Curr. Atheroscler. Rep. 2020;22(1):7. DOI: 10.1007/s11883-020-0820-8
36. Duan Y., Pan X., Luo J., Xiao X. et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front. Immunol. 2022;13:880298. DOI: 10.3389/fimmu.2022.880298
37. Attiq A., Afzal S., Ahmad W., Kandeel M. Hegemony of inflammation in atherosclerosis and coronary artery disease. Eur. J. Pharmacol. 2024;966:176338. DOI: 10.1016/j.ejphar.2024.176338
38. Galiero R., Caturano A., Vetrano E., Cesaro A. et al. Pathophysiological mechanisms and clinical evidence of relationship between nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Rev. Cardiovasc. Med. 2021;22(3):755–68. DOI: 10.31083/j.rcm2203082
39. Francisco V., Sanz M.J., Real J.T., Marques P. et al. Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets? Biology (Basel). 2022;11(8):1237. DOI: 10.3390/biology11081237
40. Kasper P., Martin A., Lang S., Kütting F. et al. NAFLD and cardiovascular diseases: a clinical review. Clin. Res. Cardiol. 2021;110(7):921–37. DOI: 10.1007/s00392-020-01709-7
41. Chew N.W.S., Chong B., Ng C.H., Kong G. et al. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Front. Genet. 2022;13:971484. DOI: 10.3389/fgene.2022.971484
42. Björnson E., Adiels M., Bergström G., Gummesson A. The relationship between genetic liver fat and coronary heart disease is explained by apoB-containing lipoproteins. Atherosclerosis. 2024;388:117397. DOI: 10.1016/j.atherosclerosis.2023.117397
43. Arslan U., Yenerçağ M. Relationship between non-alcoholic fatty liver disease and coronary heart disease. World J. Clin. Cases. 2020;8(20):4688–99. DOI: 10.12998/wjcc.v8.i20.4688
44. Dufour J.F., Caussy C., Loomba R. Combination therapy for nonalcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69(10):1877–84. DOI: 10.1136/gutjnl-2019-319104
45. Maevskaya M.V., Ivashkin V.T., Ivashkin K.V., Lunkov V.D. et al. Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy. Therapeutic Archive. 2019;91(2):109–17. (in Russian). DOI: 10.26442/00403660.2019.02.000122
46. Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 2017;67(4):829–46. DOI: 10.1016/j.jhep.2017.05.016
47. Zhang J., Fu S., Liu D., Wang Y. et al. Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2023;35(4):353–8. DOI: 10.1097/MEG.0000000000002517
48. Dai W., Xu B., Li P., Weng J. Statins for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis. Am. J. Ther. 2023;30(1):e17–25. DOI: 10.1097/MJT.0000000000001499
Review
For citations:
Tonkikh Yu.L., Vasyutin A.V., Tsukanov V.V. Modern Views about the Association of Non-Alcoholic Fatty Liver Disease and Cardiovascular Pathology. Title. 2024;23(4):27-31. (In Russ.) https://doi.org/10.31550/1727-2378-2024-23-4-27-31
Views:
17
Email this article 